Shotaro Naito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shotaro Naito has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Shinichi Uchida
Institute of Science Tokyo
14 shared publicationsSoichiro Iimori
Institute of Science Tokyo
12 shared publicationsEisei Sohara
Department of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan
9 shared publications- Shintaro Mandai
Department of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan
9 shared publications - Koichiro Susa
Department of Nephrology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan
8 shared publications Tatemitsu Rai
Department of Nephrology and Hypertension, Dokkyo Medical University
8 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wolters Kluwer Health in Kidney360
Dietary Fiber Attenuates the Association between Protein Intake and BUN in Patients with CKD
Background: While greater protein intake may contribute to BUN levels in patients with CKD, few studies have investigated whether dietary fiber modifies the association. We aimed to examine the effect modification of the association between protein intake and BUN by dietary fiber in patients with non-dialysis-dependent CKD. Methods: We included 274 patients (median age 72 years; 34% women) at three hospitals in Japan. Food group and nutrient intakes were estimated using a validated diet history questionnaire. We compared food group intake by dietary fiber tertiles. Multiple linear regression assessed the association between protein intake and BUN, adjusting for potential confounders. We performed stratified analyses by dietary fiber tertiles and interaction analyses. Results: The median (interquartile range) BUN was 24 (19–37) mg/dL, and the mean (standard deviation (SD)) estimated glomerular filtration rate was 33 (16) mL/min/1.73m 2 . The mean (SD) protein and fiber intakes were 39 (8) and 6.5 (2.2) g/1000 kcal/day, respectively. Patients with higher fiber intake had greater intake of fruits, vegetables, fish, and eggs than those with lower fiber intake. Protein intake was positively associated with natural log-transformed BUN (regression coefficient (β) = 0.05, 95% CI: 0.01 to 0.08, for one SD increase in protein intake). The association appeared stronger in the low-fiber (β = 0.08, 95% CI: 0.02 to 0.14) and medium-fiber groups (β = 0.08, 95% CI: 0.02 to 0.13), whereas it was not significant in the high-fiber group (β = 0.01, 95% CI: -0.03 to 0.06) (P for interaction = 0.10). Conclusions: The positive association between protein intake and BUN was attenuated in patients with high fiber intake, who had higher intakes of fruits, vegetables, fish, and eggs. Further studies are warranted to examine whether more liberal protein restriction is feasible in BUN management by increasing dietary fiber.
- 21 August 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessDietary Fiber Attenuates the Association between Protein Intake and BUN in Patients with CKD
Background: While greater protein intake may contribute to BUN levels in patients with CKD, few studies have investigated whether dietary fiber modifies the association. We aimed to examine the effect modification of the association between protein intake and BUN by dietary fiber in patients with non-dialysis-dependent CKD. Methods: We included 274 patients (median age 72 years; 34% women) at three hospitals in Japan. Food group and nutrient intakes were estimated using a validated diet history questionnaire. We compared food group intake by dietary fiber tertiles. Multiple linear regression assessed the association between protein intake and BUN, adjusting for potential confounders. We performed stratified analyses by dietary fiber tertiles and interaction analyses. Results: The median (interquartile range) BUN was 24 (19–37) mg/dL, and the mean (standard deviation (SD)) estimated glomerular filtration rate was 33 (16) mL/min/1.73m 2 . The mean (SD) protein and fiber intakes were 39 (8) and 6.5 (2.2) g/1000 kcal/day, respectively. Patients with higher fiber intake had greater intake of fruits, vegetables, fish, and eggs than those with lower fiber intake. Protein intake was positively associated with natural log-transformed BUN (regression coefficient (β) = 0.05, 95% CI: 0.01 to 0.08, for one SD increase in protein intake). The association appeared stronger in the low-fiber (β = 0.08, 95% CI: 0.02 to 0.14) and medium-fiber groups (β = 0.08, 95% CI: 0.02 to 0.13), whereas it was not significant in the high-fiber group (β = 0.01, 95% CI: -0.03 to 0.06) (P for interaction = 0.10). Conclusions: The positive association between protein intake and BUN was attenuated in patients with high fiber intake, who had higher intakes of fruits, vegetables, fish, and eggs. Further studies are warranted to examine whether more liberal protein restriction is feasible in BUN management by increasing dietary fiber.
- Top Cited PapersOpen Access
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e045148
Circulating Extracellular Vesicle MicroRNAs as Predictive Biomarkers for Kidney and Cardiovascular Events
Background: Chronic kidney disease ( CKD ) leads to premature mortality from cardiovascular events before kidney replacement therapy. Despite recognition of syndromes like cardiorenal anemia and cardiovascular‐kidney‐metabolic, predictive models for kidney and cardiovascular outcomes remain inadequate. This study aimed to develop a minimally invasive, risk model using circulating small extracellular vesicle‐derived mi RNAs among patients with CKD . Methods: A derivation cohort (n=36) underwent microarray‐based miRNA profiling, and a least absolute shrinkage and selection operator‐penalized Cox proportional hazards model was constructed. Validation was performed using TaqMan quantitative polymerase chain reaction in a cohort of 234 patients with CKD without kidney replacement therapy. The primary outcome was a ≥30% reduction in estimated glomerular filtration rate or progression to kidney replacement therapy. The secondary outcome included all‐cause mortality, kidney replacement therapy initiation, and major adverse cardiovascular events. Results: In the derivation cohort, 36% of patients had hypertensive glomerulosclerosis as the underlying CKD cause, increasing to 48% in the validation cohort. Twenty‐three miRNAs were significantly downregulated in advanced CKD , associated with cellular senescence, FOXO (forkhead box, class O) signaling, and cell cycle pathways. From these, 3 miRNAs — hsa‐let‐7d‐5p , hsa‐ miR ‐24‐3p , and hsa‐ miR ‐126‐3p —were selected and integrated into the final risk score with cystatin C and urinary protein levels, following optimization in the validation cohort. Lower miRNA levels were linked to cardiovascular comorbidities and cardiorenal anemia syndrome. Over a median follow‐up of 39 and 59 months, 108 kidney events and 70 composite outcomes occurred. The model effectively predicted adverse outcomes across CKD causes, further stratifying risk within cardiovascular‐kidney‐metabolic stage classifications. Conclusions: Circulating small extracellular vesicle‐derived miRNA profiles enable a noninvasive, longitudinally predictive model for adverse kidney and cardiovascular outcomes in CKD . This approach may improve early risk identification and clinical decision‐making.
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e045148
Top Cited PapersOpen AccessCirculating Extracellular Vesicle MicroRNAs as Predictive Biomarkers for Kidney and Cardiovascular Events
Background: Chronic kidney disease ( CKD ) leads to premature mortality from cardiovascular events before kidney replacement therapy. Despite recognition of syndromes like cardiorenal anemia and cardiovascular‐kidney‐metabolic, predictive models for kidney and cardiovascular outcomes remain inadequate. This study aimed to develop a minimally invasive, risk model using circulating small extracellular vesicle‐derived mi RNAs among patients with CKD . Methods: A derivation cohort (n=36) underwent microarray‐based miRNA profiling, and a least absolute shrinkage and selection operator‐penalized Cox proportional hazards model was constructed. Validation was performed using TaqMan quantitative polymerase chain reaction in a cohort of 234 patients with CKD without kidney replacement therapy. The primary outcome was a ≥30% reduction in estimated glomerular filtration rate or progression to kidney replacement therapy. The secondary outcome included all‐cause mortality, kidney replacement therapy initiation, and major adverse cardiovascular events. Results: In the derivation cohort, 36% of patients had hypertensive glomerulosclerosis as the underlying CKD cause, increasing to 48% in the validation cohort. Twenty‐three miRNAs were significantly downregulated in advanced CKD , associated with cellular senescence, FOXO (forkhead box, class O) signaling, and cell cycle pathways. From these, 3 miRNAs — hsa‐let‐7d‐5p , hsa‐ miR ‐24‐3p , and hsa‐ miR ‐126‐3p —were selected and integrated into the final risk score with cystatin C and urinary protein levels, following optimization in the validation cohort. Lower miRNA levels were linked to cardiovascular comorbidities and cardiorenal anemia syndrome. Over a median follow‐up of 39 and 59 months, 108 kidney events and 70 composite outcomes occurred. The model effectively predicted adverse outcomes across CKD causes, further stratifying risk within cardiovascular‐kidney‐metabolic stage classifications. Conclusions: Circulating small extracellular vesicle‐derived miRNA profiles enable a noninvasive, longitudinally predictive model for adverse kidney and cardiovascular outcomes in CKD . This approach may improve early risk identification and clinical decision‐making.
- 28 May 2025
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 35 (6) , 796-798
Author's Reply: “Associations Between Dietary Potassium Intake From Different Food Sources and Hyperkalemia in Patients With Chronic Kidney Disease”
- 28 May 2025
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 35 (6) , 796-798
Author's Reply: “Associations Between Dietary Potassium Intake From Different Food Sources and Hyperkalemia in Patients With Chronic Kidney Disease”
- Open Access
- 14 April 2025
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 29 (4) , 588-592
Rheocarna treatment for non‐dialysis patients
Introduction: Rheocarna has attracted attention as an alternative therapy for severe chronic limb‐threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non‐dialysis patients.Methods: Four non‐dialysis patients who received Rheocarna were studied to determine the conditions under which it was administered and its effectiveness.Results: The ulcer healed completely, but two patients required skin grafting. The treatment time and blood flow rate were 90–120 min and 50–80 mL/min, respectively. The processed volume was about 1.0 times the circulating blood volume, and the removal rate of low‐density lipoprotein and fibrinogen was about 10%–15%.Conclusion: The ulcers healed despite the removal rate of low‐density lipoprotein and fibrinogen being small. To our knowledge, this is the first report on the treatment conditions and effectiveness of Rheocarna in non‐dialysis patients.
- 14 April 2025
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 29 (4) , 588-592
Open AccessRheocarna treatment for non‐dialysis patients
Introduction: Rheocarna has attracted attention as an alternative therapy for severe chronic limb‐threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non‐dialysis patients.Methods: Four non‐dialysis patients who received Rheocarna were studied to determine the conditions under which it was administered and its effectiveness.Results: The ulcer healed completely, but two patients required skin grafting. The treatment time and blood flow rate were 90–120 min and 50–80 mL/min, respectively. The processed volume was about 1.0 times the circulating blood volume, and the removal rate of low‐density lipoprotein and fibrinogen was about 10%–15%.Conclusion: The ulcers healed despite the removal rate of low‐density lipoprotein and fibrinogen being small. To our knowledge, this is the first report on the treatment conditions and effectiveness of Rheocarna in non‐dialysis patients.
- 15 April 2024
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 34 (6) , 519-529
Associations Between Dietary Potassium Intake From Different Food Sources and Hyperkalemia in Patients With Chronic Kidney Disease
- 15 April 2024
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 34 (6) , 519-529
Associations Between Dietary Potassium Intake From Different Food Sources and Hyperkalemia in Patients With Chronic Kidney Disease
- Open Access
Association between antihypertensive combinations and postoperative mortality and functional decline: a nationwide survey of Japanese adults undergoing major surgeries
Background Considering the limited information available regarding the impact of antihypertensive classes on mortality and physical function during hospitalization, we aimed to clarify the impact of six antihypertensive classes, namely thiazide/thiazide-like diuretics (TH), calcium receptor blockers (CCBs), renin–angiotensin–aldosterone system inhibitors (RASis), mineral corticoid receptor antagonists, α-blockers, and β-blockers, on outcomes in adult patients undergoing major surgeries. Methods This study was a subanalysis of a nationwide observational cohort study involving Japanese adults undergoing major surgeries from 2018 to 2019 using an administrative claims database. We recruited 473,327 antihypertensive medication users and 376,583 nonusers aged ≥50 years who underwent six different types of surgeries, including coronary artery bypass grafting (CABG), thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery. The risk for overall death or functional decline, defined as a ≥5-point decrease in the Barthel Index score during hospitalization, was determined using multivariable logistic regression models. Results All-cause inhospital deaths occurred in 5,777 (1.2%) users and 2,657 (0.7%) nonusers. Functional decline was observed in 42,930 (9.2%) users and 22,550 (6.0%) nonusers. Among single class users, RASi use had a multivariable odds ratio (OR) of 0.77 (95% confidence interval (CI) 0.63–0.93 vs. TH) for the composite of mortality and functional decline. β-Blocker use was associated with an increased risk for functional decline (OR 1.27, 95% CI 1.01–1.60 vs. TH). Among the recipients of the two medication classes, TH/RASi usage was associated with the lowest risk for composite outcome (OR 0.68, 95% CI 0.60–0.77 vs. TH/CCB). Among the recipients of the three or more medication classes, TH/CCB/RASi or TH/CCB/RASi/other displayed the lowest odds for composite outcome (OR 0.72, 95% CI 0.49–0.82 vs. TH/CCB/other; OR 0.63, 95% CI 0.49–0.82 vs. TH/CCB/others). A stratified analysis revealed that RASi users had a lower OR for the composite outcome after major surgery categories except CABG than non-RASi users. Conclusions RASis were associated with decreased risk of postoperative mortality and functional decline regardless of the number of antihypertensive classes or surgery type. Managing hypertension through multidrug combinations, including RASis, may mitigate mortality and loss of physical function during the perioperative period. Clinical Perspective What is new? This nationwide observational cohort study of Japanese adults undergoing major surgeries from 2018 to 2019 using an administrative claims database showed that all-cause inhospital deaths occurred in 5,777 (1.2%) antihypertensive users and 2,657 (0.7%) nonusers, whereas functional decline was observed in 42,930 (9.2%) antihypertensive users and 22,550 (6.0%) nonusers. We found that an increase in the number of antihypertensive classes used, indicative of patients with treatment-resistant hypertension, was associated with a higher risk of mortality and loss of physical function, partly attributed to loop diuretic use for congestion. What are the clinical implications? This study determined combinations of antihypertensive drugs that potentially improve the outcomes of antihypertensive users undergoing major surgeries, with the favorable regimens including RASis independent of the number of antihypertensive classes used. After undergoing all major surgery categories except CABG, patients on RASis were at a lower risk of death and functional decline than those who were treated with other antihypertensive classes.
Open AccessAssociation between antihypertensive combinations and postoperative mortality and functional decline: a nationwide survey of Japanese adults undergoing major surgeries
Background Considering the limited information available regarding the impact of antihypertensive classes on mortality and physical function during hospitalization, we aimed to clarify the impact of six antihypertensive classes, namely thiazide/thiazide-like diuretics (TH), calcium receptor blockers (CCBs), renin–angiotensin–aldosterone system inhibitors (RASis), mineral corticoid receptor antagonists, α-blockers, and β-blockers, on outcomes in adult patients undergoing major surgeries. Methods This study was a subanalysis of a nationwide observational cohort study involving Japanese adults undergoing major surgeries from 2018 to 2019 using an administrative claims database. We recruited 473,327 antihypertensive medication users and 376,583 nonusers aged ≥50 years who underwent six different types of surgeries, including coronary artery bypass grafting (CABG), thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery. The risk for overall death or functional decline, defined as a ≥5-point decrease in the Barthel Index score during hospitalization, was determined using multivariable logistic regression models. Results All-cause inhospital deaths occurred in 5,777 (1.2%) users and 2,657 (0.7%) nonusers. Functional decline was observed in 42,930 (9.2%) users and 22,550 (6.0%) nonusers. Among single class users, RASi use had a multivariable odds ratio (OR) of 0.77 (95% confidence interval (CI) 0.63–0.93 vs. TH) for the composite of mortality and functional decline. β-Blocker use was associated with an increased risk for functional decline (OR 1.27, 95% CI 1.01–1.60 vs. TH). Among the recipients of the two medication classes, TH/RASi usage was associated with the lowest risk for composite outcome (OR 0.68, 95% CI 0.60–0.77 vs. TH/CCB). Among the recipients of the three or more medication classes, TH/CCB/RASi or TH/CCB/RASi/other displayed the lowest odds for composite outcome (OR 0.72, 95% CI 0.49–0.82 vs. TH/CCB/other; OR 0.63, 95% CI 0.49–0.82 vs. TH/CCB/others). A stratified analysis revealed that RASi users had a lower OR for the composite outcome after major surgery categories except CABG than non-RASi users. Conclusions RASis were associated with decreased risk of postoperative mortality and functional decline regardless of the number of antihypertensive classes or surgery type. Managing hypertension through multidrug combinations, including RASis, may mitigate mortality and loss of physical function during the perioperative period. Clinical Perspective What is new? This nationwide observational cohort study of Japanese adults undergoing major surgeries from 2018 to 2019 using an administrative claims database showed that all-cause inhospital deaths occurred in 5,777 (1.2%) antihypertensive users and 2,657 (0.7%) nonusers, whereas functional decline was observed in 42,930 (9.2%) antihypertensive users and 22,550 (6.0%) nonusers. We found that an increase in the number of antihypertensive classes used, indicative of patients with treatment-resistant hypertension, was associated with a higher risk of mortality and loss of physical function, partly attributed to loop diuretic use for congestion. What are the clinical implications? This study determined combinations of antihypertensive drugs that potentially improve the outcomes of antihypertensive users undergoing major surgeries, with the favorable regimens including RASis independent of the number of antihypertensive classes used. After undergoing all major surgery categories except CABG, patients on RASis were at a lower risk of death and functional decline than those who were treated with other antihypertensive classes.
- 1 December 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (12) , 2591-2600
National Trends in Mortality and Urgent Dialysis after Acute Hypertension in Japan From 2010 Through 2019
BACKGROUND: Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined. METHODS: This retrospective observational cohort study evaluated 50 316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan. We examined trends in incidence, urgent dialysis, mortality, and its risk factors using Poisson regression models. Using International Classification of Disease and Related Health Problems, 10th Revision codes, AHT was categorized into 5 spectrums: malignant hypertension ( n =1792), hypertensive emergency ( n =17 907), hypertensive urgency ( n =1562), hypertensive encephalopathy ( n =6593), and hypertensive heart failure (HHF; n =22 462). RESULTS: The median age of the patients was 76 years, and 54.9% were women. The total AHT incidence was 70 cases per 100 000 admission year. The absolute death rate increased from 1.83% (95% CI, 1.40–2.40) to 2.88% ([95% CI, 2.42–3.41]; Cochran-Armitage trend test, P< 0.0001). Upward trends were observed in patients aged ≥80, with lean body mass index ≤18.4, and with HHF. Urgent dialysis rates increased from 1.52% (95% CI, 1.12–2.06) to 2.60% (2.17–3.1; Cochran-Armitage trend test; P =0.0071) in 48 235 patients, excluding maintenance dialysis patients. Older age, men, lean body mass, malignant hypertension, HHF, and underlying chronic kidney disease correlated with higher mortality risk; greater hospital volume correlated with lower mortality risk; and malignant hypertension, HHF, diabetes, chronic kidney disease, and scleroderma correlated with a higher risk of urgent dialysis. CONCLUSIONS: Mortality and urgent dialysis rates following AHT have increased. Aging, complex comorbidities, and HHF-type AHT contributed to the rising trend of mortality.
- 1 December 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (12) , 2591-2600
National Trends in Mortality and Urgent Dialysis after Acute Hypertension in Japan From 2010 Through 2019
BACKGROUND: Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined. METHODS: This retrospective observational cohort study evaluated 50 316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan. We examined trends in incidence, urgent dialysis, mortality, and its risk factors using Poisson regression models. Using International Classification of Disease and Related Health Problems, 10th Revision codes, AHT was categorized into 5 spectrums: malignant hypertension ( n =1792), hypertensive emergency ( n =17 907), hypertensive urgency ( n =1562), hypertensive encephalopathy ( n =6593), and hypertensive heart failure (HHF; n =22 462). RESULTS: The median age of the patients was 76 years, and 54.9% were women. The total AHT incidence was 70 cases per 100 000 admission year. The absolute death rate increased from 1.83% (95% CI, 1.40–2.40) to 2.88% ([95% CI, 2.42–3.41]; Cochran-Armitage trend test, P< 0.0001). Upward trends were observed in patients aged ≥80, with lean body mass index ≤18.4, and with HHF. Urgent dialysis rates increased from 1.52% (95% CI, 1.12–2.06) to 2.60% (2.17–3.1; Cochran-Armitage trend test; P =0.0071) in 48 235 patients, excluding maintenance dialysis patients. Older age, men, lean body mass, malignant hypertension, HHF, and underlying chronic kidney disease correlated with higher mortality risk; greater hospital volume correlated with lower mortality risk; and malignant hypertension, HHF, diabetes, chronic kidney disease, and scleroderma correlated with a higher risk of urgent dialysis. CONCLUSIONS: Mortality and urgent dialysis rates following AHT have increased. Aging, complex comorbidities, and HHF-type AHT contributed to the rising trend of mortality.
- Open Access
National Trends in Mortality and Urgent Dialysis after Admission for Acute Hypertension in Japan from 2010 through 2019
Background: Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined. Methods: This retrospective observational cohort study evaluated 50,316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan. We examined trends in incidence, urgent dialysis, mortality and its risk factors using logistic regression models. Using ICD-10 codes, AHT was categorized into five spectrums: malignant hypertension (MHT) ( n = 1,792), hypertensive emergency ( n = 17,907), hypertensive urgency ( n = 1,562), hypertensive encephalopathy ( n = 6,593), and hypertensive heart failure (HHF) ( n = 22,462). Results: The median age of the patients was 76 years and 54.9% were female. The total AHT incidence was 70 cases per 100,000 admission year. The absolute death rate increased from 1.83% [95% confidence intervals (CI), 1.40–2.40] to 2.88% (95%CI, 2.42–3.41) [Cochran-Armitage trend test (CA), P < 0.0001]. Upward trends were observed in patients aged ≥80, with lean body mass index ≤18.4, and with HHF. Urgent dialysis rates increased from 1.52% (95%CI, 1.12–2.06) to 2.60% (2.17–3.1) (CA, P = 0.0071) in 48,235 patients, excluding maintenance dialysis patients. Older age, male, lean body mass, MHT, HHF, and underlying chronic kidney disease (CKD) correlated with higher mortality risk; greater hospital volume correlated with lower mortality risk; and MHT, HHF, diabetes mellitus, CKD, and scleroderma correlated with a higher risk of urgent dialysis. Conclusions: Mortality and urgent dialysis rates following AHT have increased. Aging, complex comorbidities, and HHF-type AHT contributed to the rising trend of mortality.
Open AccessNational Trends in Mortality and Urgent Dialysis after Admission for Acute Hypertension in Japan from 2010 through 2019
Background: Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined. Methods: This retrospective observational cohort study evaluated 50,316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan. We examined trends in incidence, urgent dialysis, mortality and its risk factors using logistic regression models. Using ICD-10 codes, AHT was categorized into five spectrums: malignant hypertension (MHT) ( n = 1,792), hypertensive emergency ( n = 17,907), hypertensive urgency ( n = 1,562), hypertensive encephalopathy ( n = 6,593), and hypertensive heart failure (HHF) ( n = 22,462). Results: The median age of the patients was 76 years and 54.9% were female. The total AHT incidence was 70 cases per 100,000 admission year. The absolute death rate increased from 1.83% [95% confidence intervals (CI), 1.40–2.40] to 2.88% (95%CI, 2.42–3.41) [Cochran-Armitage trend test (CA), P < 0.0001]. Upward trends were observed in patients aged ≥80, with lean body mass index ≤18.4, and with HHF. Urgent dialysis rates increased from 1.52% (95%CI, 1.12–2.06) to 2.60% (2.17–3.1) (CA, P = 0.0071) in 48,235 patients, excluding maintenance dialysis patients. Older age, male, lean body mass, MHT, HHF, and underlying chronic kidney disease (CKD) correlated with higher mortality risk; greater hospital volume correlated with lower mortality risk; and MHT, HHF, diabetes mellitus, CKD, and scleroderma correlated with a higher risk of urgent dialysis. Conclusions: Mortality and urgent dialysis rates following AHT have increased. Aging, complex comorbidities, and HHF-type AHT contributed to the rising trend of mortality.
- Open Access
- 4 July 2023
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 13 (1) , 51-56
Low-Density Lipoprotein Adsorption by Centrifugal Plasma Separation Can Shorten Treatment Time
Low-density lipoprotein (LDL) apheresis is effective for nephrotic syndrome in drug-resistant focal segmental glomerulosclerosis (FSGS). Dextran sulfate adsorption of LDL (DSAL) is widely used for this purpose. The Liposorber LA-15 system performs DSAL by membrane plasma separation (mDSAL) using an MA-03 plasma purification device. However, sufficient blood flow (Qb) frequently cannot be obtained from a peripheral vein with mDSAL. The recommended plasma filtration flow rate (Qf) when using the OP-05W membrane plasma separator is no more than 1/3 of Qb, giving plasma removal efficiency (PRE) of about 30%. In contrast, the centrifugal blood component separator Spectra Optia has PRE of 87–92.5% because centrifugal separation enables effective separation of plasma components even at low Qb. Here, we present the case of a man in his 40s with FSGS, for whom we began treatment with mDSAL with the intention of completing a 12-session cycle, but extended treatment times were required due to low Qb. Therefore, we switched to DSAL by centrifugation (cDSAL) using the Liposorber LA-40 system from the 6th session onward. Treatment time decreased from 190 min for the fifth session using mDSAL to 140 min for the sixth session using cDSAL. Mean treatment time also decreased from 155 ± 9 min for mDSAL (5 sessions) to 119 ± 20 min for cDSAL (7 sessions). Moreover, the LDL removal rate at a processed plasma volume was similar for both modalities. In conclusion, cDSAL can enable efficient plasma separation even with low Qb, with a comparable LDL removal rate and shorter treatment time relative to mDSAL.
- 4 July 2023
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 13 (1) , 51-56
Open AccessLow-Density Lipoprotein Adsorption by Centrifugal Plasma Separation Can Shorten Treatment Time
Low-density lipoprotein (LDL) apheresis is effective for nephrotic syndrome in drug-resistant focal segmental glomerulosclerosis (FSGS). Dextran sulfate adsorption of LDL (DSAL) is widely used for this purpose. The Liposorber LA-15 system performs DSAL by membrane plasma separation (mDSAL) using an MA-03 plasma purification device. However, sufficient blood flow (Qb) frequently cannot be obtained from a peripheral vein with mDSAL. The recommended plasma filtration flow rate (Qf) when using the OP-05W membrane plasma separator is no more than 1/3 of Qb, giving plasma removal efficiency (PRE) of about 30%. In contrast, the centrifugal blood component separator Spectra Optia has PRE of 87–92.5% because centrifugal separation enables effective separation of plasma components even at low Qb. Here, we present the case of a man in his 40s with FSGS, for whom we began treatment with mDSAL with the intention of completing a 12-session cycle, but extended treatment times were required due to low Qb. Therefore, we switched to DSAL by centrifugation (cDSAL) using the Liposorber LA-40 system from the 6th session onward. Treatment time decreased from 190 min for the fifth session using mDSAL to 140 min for the sixth session using cDSAL. Mean treatment time also decreased from 155 ± 9 min for mDSAL (5 sessions) to 119 ± 20 min for cDSAL (7 sessions). Moreover, the LDL removal rate at a processed plasma volume was similar for both modalities. In conclusion, cDSAL can enable efficient plasma separation even with low Qb, with a comparable LDL removal rate and shorter treatment time relative to mDSAL.